20,99 €
inkl. MwSt.
Versandfertig in 1-2 Wochen
10 °P sammeln
Andere Kunden interessierten sich auch für
![Efficacy of Mahanimba Moola Ghanavati in Pain and Inflammation in Rats]( "Efficacy of Mahanimba Moola Ghanavati in Pain and Inflammation in Rats")
Efficacy of Mahanimba Moola Ghanavati in Pain and Inflammation in Rats26,99 €![Handbook of Research on the Efficacy of Training Programs and Systems in Medical Education]( "Handbook of Research on the Efficacy of Training Programs and Systems in Medical Education")
Handbook of Research on the Efficacy of Training Programs and Systems in Medical Education476,99 €![On The Efficacy Of Crotalus Horridus In Yellow Fever]( "On The Efficacy Of Crotalus Horridus In Yellow Fever")
On The Efficacy Of Crotalus Horridus In Yellow Fever23,99 €![Analysis of self-efficacy in Parkinson's patients who exercise]( "Analysis of self-efficacy in Parkinson's patients who exercise")
Analysis of self-efficacy in Parkinson's patients who exercise29,99 €![Considerations On the Efficacy of Electricity in Removing Female Obstructions]( "Considerations On the Efficacy of Electricity in Removing Female Obstructions")
Considerations On the Efficacy of Electricity in Removing Female Obstructions33,99 €![A curriculim to increase the self-efficacy in reproductive health of college females]( "A curriculim to increase the self-efficacy in reproductive health of college females")
A curriculim to increase the self-efficacy in reproductive health of college females47,95 €![Therapeutic Uses and Efficacy of Botulinum Toxin in Orofacial Medicine]( "Therapeutic Uses and Efficacy of Botulinum Toxin in Orofacial Medicine")
Therapeutic Uses and Efficacy of Botulinum Toxin in Orofacial Medicine61,99 €
Secondary hyperparathyroidism (sHPT) is common in hemodialysis (HD) patients. The present study aimed to evaluate the efficacy and safety profile of etelcalcetide, a new peptide calcium-sensing receptor (CaSR) agonist in an observational study for the treatment of sHPT in CKD patients on HD.60 HD stable patients with sHPT were received etelcalcetide for 10 months. PTH levels, Ca, Ph, alb were measured before starting etelcalcetide and every month until the end of the protocol. Heart function was also evaluated. The primary outcome was estimation of PTH concentrations at the end of the treatment period. Secondary outcomes were monitoring of corrected serum Ca, ph. Adverse events were also evaluated. PTH significantly decreased from the first month of the treatment with etelcalcetide until the end of the study period. We also noticed significant reduction of the ph levels even from the second month of treatment. This trend also carried out for 8 months. Heart function remained stable. Ca levels remained in accepted area. None of the patients dropped out due to adverse events.Etelcalcetide is safe, well tolerated and effective in reducing PTH in HD patients with sHPT.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.